BRCA1-related ovarian cancer
GPTKB entity
Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Oncology
|
| gptkbp:associated_with |
gptkb:BRCA1_gene
|
| gptkbp:demographics |
More common in women
Higher incidence in Ashkenazi Jewish women |
| gptkbp:diagnosis |
Biopsy
Ultrasound CT scan Varies by stage Pelvic examination Higher risk of recurrence |
| gptkbp:gene_mutation |
gptkb:BRCA1_mutation
gptkb:BRCA2_mutation |
| https://www.w3.org/2000/01/rdf-schema#label |
BRCA1-related ovarian cancer
|
| gptkbp:is_involved_in |
gptkb:Ovarian_Cancer_Research_Alliance
gptkb:BRCA1_and_BRCA2_Mutation_Support_Group BRCA1 and BRCA2 Support Group |
| gptkbp:prevention |
Genetic testing
Regular screenings Prophylactic surgery |
| gptkbp:public_awareness |
gptkb:BRCA_Awareness_Day
gptkb:National_Ovarian_Cancer_Coalition gptkb:Ovarian_Cancer_National_Alliance gptkb:Ovarian_Cancer_Awareness_Month |
| gptkbp:research_focus |
Clinical trials
Patient education Genetic counseling Quality of life studies New therapies Long-term survivorship |
| gptkbp:risk_factor |
gptkb:Endometriosis
Obesity Hormone replacement therapy Age 50 or older Family history of breast cancer Family history of ovarian cancer Nulliparity |
| gptkbp:risk_percentage |
Increased risk with age
Up to 44% lifetime risk |
| gptkbp:screenings |
Annual pelvic exams
CA-125 blood test Transvaginal ultrasound |
| gptkbp:symptoms |
Fatigue
Frequent urination Pelvic pain Abdominal bloating Difficulty eating Changes in bowel habits Menstrual irregularities Unexplained weight loss |
| gptkbp:treatment |
gptkb:immunotherapy
gptkb:hospice_care gptkb:surgery Chemotherapy Radiation therapy Hormonal therapy Targeted therapy Combination therapy Genetic therapy Clinical trials for new drugs |
| gptkbp:bfsParent |
gptkb:BRCA1_protein
|
| gptkbp:bfsLayer |
8
|